坤泰胶囊与雌激素替代疗法联合治疗围绝经期综合征的疗效分析

丁坤琼; 毛世华; 谈宗国

doi:10.13898/j.cnki.issn.1000-2200.2018.09.013

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

坤泰胶囊与雌激素替代疗法联合治疗围绝经期综合征的疗效分析

丁坤琼 , 毛世华 , 谈宗国

文章导航 > 蚌埠医学院学报 > 2018, 43 > 9: (1163-1165)

引用本文:

Citation:

坤泰胶囊与雌激素替代疗法联合治疗围绝经期综合征的疗效分析

重庆市三峡中心医院妇产科, 404000

作者简介: 丁坤琼(1976-),女,主治医师.

中图分类号: R711.75

The curative effect of Kuntai capsule combined with estrogen replacement therapy in the treatment of menopause syndrome

Department of Gynaecology and Obstetrics, Chongqing Three Gorges Center Hospital, Chongqing 404000, China
CLC number: R711.75

摘要: 目的：观察坤泰胶囊联合雌激素替代疗法治疗围绝经期综合征（MPS）的临床疗效及安全性。方法：选取160例MPS病人，按照随机数字法随机分为对照组和观察组，每组80例。对照组给予常规药物戊酸雌二醇2 mg，1次/天；观察组给予戊酸雌二醇1 mg，1次/天，且口服坤泰胶囊4粒/次，3次/天，2组均于治疗后10 d给予安宫黄体酮口服，每次2 mg，每天1次。2组均治疗3个治疗周期。观察2组治疗前后的改良Kupperman症状评分及检测其治疗前后血清雌激素（E₂）、阴道细胞成熟值、子宫内膜厚度、血脂等情况。记录消化道、阴道出血、乳房胀痛症状。结果：治疗后2组Kupperman评分均较治疗前明显下降（P<0.01），且观察组下降更为明显（P<0.01）。治疗3个月后，观察组治疗总有效率为90.0%，高于对照组的72.5%（P<0.01）。2组治疗后卵泡刺激素、黄体生成素、E₂与治疗前相比均显著变化（P<0.01），且观察组治疗后卵泡刺激素、E₂改善情况优于对照组治疗后（P<0.05）。观察组不良反应率为3.75%，低于对照组的12.50%（P<0.05）。结论：坤泰胶囊联合小剂量雌激素替代疗法治疗MPS，不仅可显著改善病人的临床症状，且安全性高，值得临床推广。
- 围绝经期综合征 /
- 坤泰胶囊 /
- 雌激素
Abstract: Objective:To observe the clinical effects and safety of the Kuntai capsule combined with estrogen in the treatment of menopause syndrome(MPS).Methods:One hundred and sixty MPS patients were randomly divided into the control group and observation group according to the random number method(80 cases each group).The control group was treated with conventional drug(2 mg/d of pentanoic acid estradiol),and the observation group was treated with 1 mg/d of pentanoic acid estradiol(once a day) combined with Kuntai capsule(4 granules/time,3 times/d) by oral.After 10 d of treatment,two groups were treated with medroxyprogesterone acetate(2 mg/time,once a day) by oral for 3 treatment cycles.The Kupperman symptom score,serum level of estrogen(E₂),vaginal cell mature value,endometrial thickness and blood lipid in two groups between before and after treatment were compared,and the digestive tract,vaginal bleeding and breast pain symptoms in two groups were recorded.Results:After treatment,the Kupperman scores in two groups significantly decreased compared with before treatment(P<0.01),which in observation group was more significant(P<0.01).After 3 months of treatment,the total effective rate in observation group(90.0%) was higher than that in control group(72.5%)(P<0.01).After treatment,there were significant changes in follicle stimulating hormone,luteinizing hormone and E₂(P<0.01),and the improvement of follicle stimulating hormone and E₂ in observation group was better than that in control group(P<0.05).The adverse reaction rate in observation group(3.75%) was lower than that in control group(12.50%)(P<0.05).Conclusions:Kuntai capsule combined with small dose of estrogen replacement therapy in treating MPS can significantly improve the patient's clinical symptoms,which is safe and worthy of clinical promotion.
- menopause syndrome /
- Kuntai capsule /
- estrogen

[1]	乔平,何贵翔.中医药治疗围绝经期综合征研究进展[J].中医药信息,2011,28(3):139.
[2]	钱静华.陆文彬治疗围绝经期综合征经验[J].浙江中医杂志,2012,47(8):596.
[3]	曹泽毅.中华妇产科学[M].2版.北京:人民卫生出版社,2004:58.
[4]	郑筱萸.中药新药临床指导原则[S].北京:中国医药科技出版社,2002,238.
[5]	马立新,赵继鹏.左归丸合酸枣仁汤治疗围绝经期灼口综合征的分析[J].中国美容医学,2012,21(8):259.
[6]	李存存,王晶晶,陈潮,等.坤泰胶囊与激素替代疗法治疗更年期综合征有效性和安全性比较的Meta分析[J].中国中西医结合杂志,2013,33(9):1183.
[7]	李瑞珠.探究坤泰胶囊联用雌激素替代疗法治疗围绝经期综合征临床疗效[J].中医药学报,2014,42(3):146.
[8]	满玉晶,赵丽妍,陈月,等.围绝经期综合征中西医发病机制探究[J].中国中医药现代远程教育,2011,9(13):138.
[9]	周华锋.地屈孕酮联合坤泰胶囊治疗女性更年期综合征的临床研究[J].中国妇幼保健,2014,29(21):3390.
[10]	王红英,支聪聪,赵春兰,等.坤泰胶囊对子宫切除术后妇女卵巢功能及围绝经期症状的影响[J].医学研究与教育,2013,6(12):112.

[1]	王习习 , 李金芝 . 影响围绝经期综合征发生的生物-心理-社会因素的研究进展. 蚌埠医学院学报, 2016, 41(3): 419-420. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.046
[2]	郑冬雪 , 刘明洁 , 胡紫薇 , 王会娜 , 李志强 , 江步君 , 王立群 . 蚌埠市围绝经期妇女健康状况及其影响因素研究. 蚌埠医学院学报, 2021, 46(8): 1109-1115. doi: 10.13898/j.cnki.issn.1000-2200.2021.08.031
[3]	李群 . 改进养膜方联合雌激素对肾虚血瘀型薄型子宫内膜病人子宫内膜容受性和子宫血流动力学的影响. 蚌埠医学院学报, 2017, 42(11): 1517-1521. doi: 10.13898/j.cnki.issn.1000-2200.2017.11.025
[4]	吴粉兰 , 丁小梅 . 雌孕激素反向添加法在GnRHa治疗子宫内膜异位症中的疗效及安全性研究. 蚌埠医学院学报, 2018, 43(12): 1616-1619. doi: 10.13898/j.cnki.issn.1000-2200.2018.12.022
[5]	李志杰 , 杜昌国 . 乳腺良恶性疾病患者血清催乳素、雌二醇水平的比较及其临床意义. 蚌埠医学院学报, 2013, 37(8): 1005-1006.
[6]	耿鹏 . 人绝经期促性腺激素联合宫腔内人工授精治疗多囊卵巢综合征不孕47例. 蚌埠医学院学报, 2009, 34(11): 1000-1001.
[7]	雷亚平 , 胡雪涛 . 围绝经期子宫异常出血子宫内膜病理变化分析. 蚌埠医学院学报, 2015, 40(3): 367-368. doi: 10.13898/j.cnki.issn.1000-2200.2015.03.024
[8]	郭苏阳 , 李群 . 雌激素受体亚型表达与子宫内膜癌预后的关系. 蚌埠医学院学报, 2009, 34(10): 895-897.
[9]	白洁 , 程骋 , 孙翾 , 李金芝 . 围绝经期护士自我健康管理现状及相关影响因素的探究. 蚌埠医学院学报, 2017, 42(9): 1267-1270. doi: 10.13898/j.cnki.issn.1000-2200.2017.09.035
[10]	潘佳佳 , 谈玖婷 , 刘微丽 . 急性呼吸窘迫综合征病人甲状腺激素水平对预后的影响. 蚌埠医学院学报, 2018, 43(12): 1588-1590. doi: 10.13898/j.cnki.issn.1000-2200.2018.12.014
[11]	张晓静 , 刘先富 , 陈延松 , 郭伟 . DNA2基因表达与乳腺癌恶性程度及雌激素受体表达的关系. 蚌埠医学院学报, 2017, 42(11): 1469-1471,1475. doi: 10.13898/j.cnki.issn.1000-2200.2017.11.011
[12]	陈金璋 , 张继平 , 殷宪刚 , 李国霞 , 徐流河 , 杨艳丽 , 赵澄泉 , 任兴昌 , 薛德彬 . 乳腺浸润性大汗腺癌雌激素受体、孕激素受体和人表皮生长因子受体2的表达. 蚌埠医学院学报, 2011, 36(8): 839-841.
[13]	袁帅 , 袁晓航 , 宋颖华 . 曼月乐环联合屈螺酮炔雌醇片治疗围绝经期功能失调性子宫出血的疗效观察. 蚌埠医学院学报, 2017, 42(12): 1641-1644. doi: 10.13898/j.cnki.issn.1000-2200.2017.12.021
[14]	李春梅 , 陈频 , 林忆阳 , 徐向进 . 维格列汀对2型糖尿病围绝经期妇女骨代谢及骨密度水平的影响. 蚌埠医学院学报, 2019, 44(11): 1484-1486. doi: 10.13898/j.cnki.issn.1000-2200.2019.11.013
[15]	马岳红 . 促肾上腺皮质激素治疗原发性肾病综合征频复发及激素依赖患儿的护理. 蚌埠医学院学报, 2014, 38(4): 547-548.
[16]	瓮生彬 , 张建波 , 张淑艳 , 郑超 , 白杰 , 徐德龙 . 血管内皮生长因子、雌激素受体在甲状腺乳头状癌和甲状腺滤泡状腺瘤组织中的表达及其意义. 蚌埠医学院学报, 2010, 35(1): 37-39.
[17]	葛嫣然 , 邵宏超 , 王福海 . 雌激素对兔视网膜缺血再灌注损伤中视网膜神经节细胞凋亡及bcl-2表达的影响. 蚌埠医学院学报, 2015, 40(1): 11-13. doi: 10.13898/j.cnki.issn.1000-2200.2015.01.004
[18]	于艳丽 , 葛秋迎 , 于秀娟 , 王金梅 . 多囊卵巢综合征血抗苗勒管激素与临床内分泌指标相关性分析. 蚌埠医学院学报, 2018, 43(6): 730-733. doi: 10.13898/j.cnki.issn.1000-2200.2018.06.010
[19]	钱艺美 , 缪铃 . 心血管病变对多囊卵巢综合征育龄妇女糖脂代谢、胰岛素抵抗及性激素的影响. 蚌埠医学院学报, 2021, 46(2): 225-227, 231. doi: 10.13898/j.cnki.issn.1000-2200.2021.02.023
[20]	叶志恒 , 储小宏 , 贾丽 , 赵广碧 , 吴帮庆 . 绝经后糖耐量减低者性激素的变化. 蚌埠医学院学报, 2009, 34(1): 59-60.

点击查看大图

计量

文章访问数: 3956
HTML全文浏览量: 579
PDF下载量: 11
被引次数: 0

坤泰胶囊与雌激素替代疗法联合治疗围绝经期综合征的疗效分析

作者简介: 丁坤琼(1976-),女,主治医师.

重庆市三峡中心医院妇产科, 404000

收稿日期: 2015-08-09
录用日期: 2018-07-19

关键词:

摘要: 目的：观察坤泰胶囊联合雌激素替代疗法治疗围绝经期综合征（MPS）的临床疗效及安全性。方法：选取160例MPS病人，按照随机数字法随机分为对照组和观察组，每组80例。对照组给予常规药物戊酸雌二醇2 mg，1次/天；观察组给予戊酸雌二醇1 mg，1次/天，且口服坤泰胶囊4粒/次，3次/天，2组均于治疗后10 d给予安宫黄体酮口服，每次2 mg，每天1次。2组均治疗3个治疗周期。观察2组治疗前后的改良Kupperman症状评分及检测其治疗前后血清雌激素（E₂）、阴道细胞成熟值、子宫内膜厚度、血脂等情况。记录消化道、阴道出血、乳房胀痛症状。结果：治疗后2组Kupperman评分均较治疗前明显下降（P<0.01），且观察组下降更为明显（P<0.01）。治疗3个月后，观察组治疗总有效率为90.0%，高于对照组的72.5%（P<0.01）。2组治疗后卵泡刺激素、黄体生成素、E₂与治疗前相比均显著变化（P<0.01），且观察组治疗后卵泡刺激素、E₂改善情况优于对照组治疗后（P<0.05）。观察组不良反应率为3.75%，低于对照组的12.50%（P<0.05）。结论：坤泰胶囊联合小剂量雌激素替代疗法治疗MPS，不仅可显著改善病人的临床症状，且安全性高，值得临床推广。

English Abstract

The curative effect of Kuntai capsule combined with estrogen replacement therapy in the treatment of menopause syndrome

Department of Gynaecology and Obstetrics, Chongqing Three Gorges Center Hospital, Chongqing 404000, China

Received Date: 2015-08-09
Accepted Date: 2018-07-19

Abstract: Objective:To observe the clinical effects and safety of the Kuntai capsule combined with estrogen in the treatment of menopause syndrome(MPS).Methods:One hundred and sixty MPS patients were randomly divided into the control group and observation group according to the random number method(80 cases each group).The control group was treated with conventional drug(2 mg/d of pentanoic acid estradiol),and the observation group was treated with 1 mg/d of pentanoic acid estradiol(once a day) combined with Kuntai capsule(4 granules/time,3 times/d) by oral.After 10 d of treatment,two groups were treated with medroxyprogesterone acetate(2 mg/time,once a day) by oral for 3 treatment cycles.The Kupperman symptom score,serum level of estrogen(E₂),vaginal cell mature value,endometrial thickness and blood lipid in two groups between before and after treatment were compared,and the digestive tract,vaginal bleeding and breast pain symptoms in two groups were recorded.Results:After treatment,the Kupperman scores in two groups significantly decreased compared with before treatment(P<0.01),which in observation group was more significant(P<0.01).After 3 months of treatment,the total effective rate in observation group(90.0%) was higher than that in control group(72.5%)(P<0.01).After treatment,there were significant changes in follicle stimulating hormone,luteinizing hormone and E₂(P<0.01),and the improvement of follicle stimulating hormone and E₂ in observation group was better than that in control group(P<0.05).The adverse reaction rate in observation group(3.75%) was lower than that in control group(12.50%)(P<0.05).Conclusions:Kuntai capsule combined with small dose of estrogen replacement therapy in treating MPS can significantly improve the patient's clinical symptoms,which is safe and worthy of clinical promotion.